Effect of dapagliflozin on renal function in patients with hypertension and coronary atherosclerotic heart disease after coronary angiography or interventional therapy
He Ming-hao
Yang Yi-ping
Fu Shen-wen
Abstract：Objective To investigate the effect of dapagliflozin on renal function in patients with hypertension and coronary atherosclerotic heart disease after undergoing coronary angiography or interventions.Methods A total of 146 patients with hy-pertension and coronary atherosclerotic heart disease admitted to Jinhua Central Hospital from May 2022 to May 2024 for coronary angiography or interventional treatment were enrolled in this study.They were divided into the control group(72 patients)receiv-ing standard therapy including clopidogrel,aspirin and statins,and the observation group(74 patients)receiving the same plus dapagliflozin.The study assessed clinical conditions,and renal function indicators before and after interventional therapy,while the multivariate logistic regression method was adopted to identify factors affecting post-procedure renal function.Results The differences in renal injury molecule-1,serum creatinine,and estimated glomerular filtration rate in the observation group((6.50±2.14)ng·L-1,(6.92±1.95)μmol·L-1,(3.59±0.64)mL·min-1·1.73m-2)before and after the therapy were smaller than those in the con-trol group((8.23±3.05)ng·L-1,(12.25±2.16)μmol·L-1,(5.44±1.29)mL·min-1·1.73m-2),which were statistically significant(t=3.976,15.659,11.022,all P<0.05).Contrast nephropathy incidence was 4.05%(3/74)in the observation group,which was lower than that of 15.28%(11/72)in the control group,and the difference was statistically significant(χ2=5.303,P=0.021).Out of all pa-tients,14 developed contrast nephropathy,while 132 did not.Univariate and multivariate Logistic regression analysis indicated that dapagliflozin was a protective factor for renal function after coronary angiography or interventional treatment(OR=0.240,P=0.036).Conclusion Dapagliflozin can improve renal function indicators in hypertensive patients with coronary atherosclerotic heart disease after coronary angiography or interventions,which is a protective factor for renal function.
Keywords：DapagliflozinHypertensionCoronary atherosclerotic heart diseaseContrast nephropathyInterventional therapySerum creatinine
Publication Date：2025-02-24
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 18-20,65 )